89 related articles for article (PubMed ID: 21068155)
1. Utilization of a mutagenesis screen to generate mouse models of hyperaldosteronism.
Spyroglou A; Wagner S; Gomez-Sanchez C; Rathkolb B; Wolf E; Manolopoulou J; Reincke M; Bidlingmaier M; Hrabé de Angelis M; Beuschlein F
Endocrinology; 2011 Jan; 152(1):326-31. PubMed ID: 21068155
[TBL] [Abstract][Full Text] [Related]
2. Genetic characterization of a mouse line with primary aldosteronism.
Perez-Rivas LG; Rhayem Y; Sabrautzki S; Hantel C; Rathkolb B; Hrabě de Angelis M; Reincke M; Beuschlein F; Spyroglou A
J Mol Endocrinol; 2017 Feb; 58(2):67-78. PubMed ID: 27965370
[TBL] [Abstract][Full Text] [Related]
3. Enu mouse mutagenesis: generation of mouse mutants with aberrant plasma IgE levels.
Alessandrini F; Jakob T; Wolf A; Wolf E; Balling R; Hrabé de Angelis M; Ring J; Behrendt H
Int Arch Allergy Immunol; 2001; 124(1-3):25-8. PubMed ID: 11306917
[TBL] [Abstract][Full Text] [Related]
4. Animal models of primary aldosteronism.
Beuschlein F
Ann Endocrinol (Paris); 2009 Jun; 70(3):168-72. PubMed ID: 19296925
[TBL] [Abstract][Full Text] [Related]
5. Animal models of primary aldosteronism.
Beuschlein F
Horm Metab Res; 2010 Jun; 42(6):446-9. PubMed ID: 20013646
[TBL] [Abstract][Full Text] [Related]
6. Generation of N-ethyl-N-nitrosourea-induced mouse mutants with deviations in plasma enzyme activities as novel organ-specific disease models.
Aigner B; Rathkolb B; Klaften M; Sedlmeier R; Klempt M; Wagner S; Michel D; Mayer U; Klopstock T; de Angelis MH; Wolf E
Exp Physiol; 2009 Apr; 94(4):412-21. PubMed ID: 19151073
[TBL] [Abstract][Full Text] [Related]
7. Large-scale albuminuria screen for nephropathy models in chemically induced mouse mutants.
Rathkolb B; Tran TV; Klempt M; Hrabé de Angelis M; Wanke R; Wolf E; Aigner B
Nephron Exp Nephrol; 2005; 100(4):e143-9. PubMed ID: 15849479
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience.
Pallauf A; Schirpenbach C; Zwermann O; Fischer E; Morak M; Holinski-Feder E; Hofbauer L; Beuschlein F; Reincke M
Horm Metab Res; 2012 Mar; 44(3):215-20. PubMed ID: 22274719
[TBL] [Abstract][Full Text] [Related]
9. An update on novel mechanisms of primary aldosteronism.
Zennaro MC; Boulkroun S; Fernandes-Rosa F
J Endocrinol; 2015 Feb; 224(2):R63-77. PubMed ID: 25424518
[TBL] [Abstract][Full Text] [Related]
10. Identification of 17 hearing impaired mouse strains in the TMGC ENU-mutagenesis screen.
Kermany MH; Parker LL; Guo YK; Miller D; Swanson DJ; Yoo TJ; Goldowitz D; Zuo J
Hear Res; 2006 Oct; 220(1-2):76-86. PubMed ID: 16949226
[TBL] [Abstract][Full Text] [Related]
11. Screen for alterations of iron related parameters in N-ethyl-N-nitrosourea-treated mice identified mutant lines with increased plasma ferritin levels.
Rathkolb B; Klempt M; Sabrautzki S; Michel D; Klaften M; Laufs J; Sedlmeier R; Hans W; Fuchs H; Muckenthaler MU; Horsch M; Campagna DR; Fleming M; Hrabé de Angelis M; Wolf E; Aigner B
Biometals; 2015 Apr; 28(2):293-306. PubMed ID: 25636453
[TBL] [Abstract][Full Text] [Related]
12. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance.
Stowasser M; Bachmann AW; Huggard PR; Rossetti TR; Gordon RD
J Clin Endocrinol Metab; 2000 Jun; 85(6):2160-6. PubMed ID: 10852446
[TBL] [Abstract][Full Text] [Related]
13. Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet.
Wang Q; Clement S; Gabbiani G; Horisberger JD; Burnier M; Rossier BC; Hummler E
Am J Physiol Renal Physiol; 2004 Jun; 286(6):F1178-84. PubMed ID: 14761862
[TBL] [Abstract][Full Text] [Related]
14. Clinical, biochemical and genetic approaches to the detection of familial hyperaldosteronism type I.
Stowasser M; Bachmann AW; Jonsson JR; Tunny TJ; Klemm SA; Gordon RD
J Hypertens; 1995 Dec; 13(12 Pt 2):1610-3. PubMed ID: 8903619
[TBL] [Abstract][Full Text] [Related]
15. A sensitized screen of N-ethyl-N-nitrosourea-mutagenized mice identifies dominant mutants predisposed to diabetic nephropathy.
Tchekneva EE; Rinchik EM; Polosukhina D; Davis LS; Kadkina V; Mohamed Y; Dunn SR; Sharma K; Qi Z; Fogo AB; Breyer MD
J Am Soc Nephrol; 2007 Jan; 18(1):103-12. PubMed ID: 17151334
[TBL] [Abstract][Full Text] [Related]
16. N-ethyl-N-nitrosourea-based generation of mouse models for mutant G protein-coupled receptors.
Grosse J; Tarnow P; Römpler H; Schneider B; Sedlmeier R; Huffstadt U; Korthaus D; Nehls M; Wattler S; Schöneberg T; Biebermann H; Augustin M
Physiol Genomics; 2006 Aug; 26(3):209-17. PubMed ID: 16720677
[TBL] [Abstract][Full Text] [Related]
17. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism.
Fallo F; Pilon C; Williams TA; Sonino N; Morra Di Cella S; Veglio F; De Iasio R; Montanari P; Mulatero P
J Hum Hypertens; 2004 Jan; 18(1):47-51. PubMed ID: 14688810
[TBL] [Abstract][Full Text] [Related]
18. Optimal N-ethyl-N-nitrosourea (ENU) doses for inbred mouse strains.
Weber JS; Salinger A; Justice MJ
Genesis; 2000 Apr; 26(4):230-3. PubMed ID: 10748459
[TBL] [Abstract][Full Text] [Related]
19. Optimizing screening and mating strategies for phenotype-driven recessive N-ethyl-N-nitrosourea screens in mice.
Barbaric I; Dear TN
J Am Assoc Lab Anim Sci; 2007 Nov; 46(6):44-9. PubMed ID: 17994672
[TBL] [Abstract][Full Text] [Related]
20. Gender-, strain-, and inheritance-dependent variation in aldosterone secretion in mice.
Spyroglou A; Sabrautzki S; Rathkolb B; Bozoglu T; Hrabé de Angelis M; Reincke M; Bidlingmaier M; Beuschlein F
J Endocrinol; 2012 Dec; 215(3):375-81. PubMed ID: 23015642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
